AM 580 (CAS 102121-60-8)

AM 580 is a selective retinoic acid analog that has gained significance as useful in vitro as a RARα agonist. Studies have indicated that RARα activation enhances the signaling of the RARα receptor, leading to the inhibition of intracellular and extracellular amyloid-β accumulation. Furthermore, RARα activation promotes the expression of disintegrin and metalloprotease. The accumulation of amyloid-β is a prominent characteristic of Alzheimer′s disease (AD), and AM 580 can serve as a valuable compound for in vitro studies on this disease. By utilizing AM 580, researchers can investigate the underlying mechanisms and potential therapeutic interventions associated with amyloid-β accumulation in AD. AM 580 also exhibits immunomodulatory properties. It stimulates the functions of interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), while suppressing the production of interleukin-12 (IL-12) and interferon-gamma (IFNγ). These effects suggest that AM 580 has the potential to influence immune responses and inflammatory processes. Alternate research studies propose that AM 580 may have inhibitory effects on tumor proliferation by reducing the levels of RARγ and activating RARβ. These findings imply the potential utility of AM 580 in investigating and understanding the molecular mechanisms underlying tumor growth and development. The precise molecular mechanisms underlying the effects of AM 580 are still being elucidated. Further research is needed to fully understand interactions with RARα and its downstream effects on gene expression and cellular processes.